Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.10
NYSE:DGX's Cash-to-Debt is ranked lower than
92% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. NYSE:DGX: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: 0.44
Current: 0.1
0.02
0.44
Equity-to-Asset 0.46
NYSE:DGX's Equity-to-Asset is ranked lower than
65% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:DGX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.45 Max: 0.56
Current: 0.46
0.3
0.56
Interest Coverage 8.87
NYSE:DGX's Interest Coverage is ranked lower than
68% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. NYSE:DGX: 8.87 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 9.27
Current: 8.87
5.74
9.27
Piotroski F-Score: 6
Altman Z-Score: 3.62
Beneish M-Score: -2.61
WACC vs ROIC
7.78%
9.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.99
NYSE:DGX's Operating Margin % is ranked higher than
87% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. NYSE:DGX: 16.99 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 16.93 Max: 20.64
Current: 16.99
13.22
20.64
Net Margin % 8.57
NYSE:DGX's Net Margin % is ranked higher than
76% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NYSE:DGX: 8.57 )
Ranked among companies with meaningful Net Margin % only.
NYSE:DGX' s Net Margin % Range Over the Past 10 Years
Min: 5.07  Med: 8.3 Max: 11.88
Current: 8.57
5.07
11.88
ROE % 13.82
NYSE:DGX's ROE % is ranked higher than
76% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. NYSE:DGX: 13.82 )
Ranked among companies with meaningful ROE % only.
NYSE:DGX' s ROE % Range Over the Past 10 Years
Min: 10.72  Med: 14.94 Max: 20.93
Current: 13.82
10.72
20.93
ROA % 6.38
NYSE:DGX's ROA % is ranked higher than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. NYSE:DGX: 6.38 )
Ranked among companies with meaningful ROA % only.
NYSE:DGX' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 6.64 Max: 9.31
Current: 6.38
4.78
9.31
ROC (Joel Greenblatt) % 109.19
NYSE:DGX's ROC (Joel Greenblatt) % is ranked higher than
91% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. NYSE:DGX: 109.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 88  Med: 116.04 Max: 143.99
Current: 109.19
88
143.99
3-Year Revenue Growth Rate 4.30
NYSE:DGX's 3-Year Revenue Growth Rate is ranked higher than
51% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. NYSE:DGX: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 8.1 Max: 15.4
Current: 4.3
3.5
15.4
3-Year EBITDA Growth Rate -2.40
NYSE:DGX's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. NYSE:DGX: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.4  Med: 9.3 Max: 44.4
Current: -2.4
-2.4
44.4
3-Year EPS without NRI Growth Rate -5.30
NYSE:DGX's 3-Year EPS without NRI Growth Rate is ranked lower than
53% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. NYSE:DGX: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.3  Med: 9.4 Max: 61.5
Current: -5.3
-5.3
61.5
GuruFocus has detected 5 Warning Signs with Quest Diagnostics Inc $NYSE:DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:DGX's 10-Y Financials

Financials (Next Earnings Date: 2017-04-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DGX Guru Trades in Q1 2016

John Rogers 747,094 sh (+7.77%)
Bernard Horn 61,733 sh (unchged)
Murray Stahl 7,350 sh (unchged)
John Hussman 2,000 sh (unchged)
Ray Dalio Sold Out
Jeff Auxier 69,955 sh (-0.45%)
Charles Brandes 162,685 sh (-3.73%)
Chris Davis 3,314,772 sh (-7.69%)
Joel Greenblatt 249,221 sh (-7.79%)
Scott Black 31,347 sh (-11.08%)
David Dreman 14,059 sh (-28.32%)
Paul Tudor Jones 6,786 sh (-35.67%)
Pioneer Investments 123,162 sh (-44.16%)
» More
Q2 2016

DGX Guru Trades in Q2 2016

Pioneer Investments 184,754 sh (+50.01%)
Jeff Auxier 69,955 sh (unchged)
John Hussman 2,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Murray Stahl 7,300 sh (-0.68%)
Chris Davis 3,279,494 sh (-1.06%)
David Dreman 13,474 sh (-4.16%)
Scott Black 30,000 sh (-4.30%)
Charles Brandes 146,794 sh (-9.77%)
Paul Tudor Jones 6,000 sh (-11.58%)
Joel Greenblatt 177,438 sh (-28.80%)
John Rogers 454,535 sh (-39.16%)
» More
Q3 2016

DGX Guru Trades in Q3 2016

Lee Ainslie 37,510 sh (New)
John Hussman 76,500 sh (+3725.00%)
Joel Greenblatt 308,220 sh (+73.71%)
Paul Tudor Jones 6,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Pioneer Investments Sold Out
Jeff Auxier 69,530 sh (-0.61%)
Murray Stahl 7,250 sh (-0.68%)
Charles Brandes 141,534 sh (-3.58%)
David Dreman 12,702 sh (-5.73%)
Scott Black 28,269 sh (-5.77%)
John Rogers 404,984 sh (-10.90%)
Chris Davis 239,896 sh (-92.68%)
» More
Q4 2016

DGX Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 7,625 sh (New)
Jim Simons 58,900 sh (New)
John Hussman 100,000 sh (+30.72%)
Charles Brandes 141,713 sh (+0.13%)
Bernard Horn 61,733 sh (unchged)
Paul Tudor Jones Sold Out
Lee Ainslie Sold Out
Murray Stahl 6,900 sh (-4.83%)
David Dreman 11,851 sh (-6.70%)
John Rogers 371,880 sh (-8.17%)
Chris Davis 203,698 sh (-15.09%)
Jeff Auxier 53,995 sh (-22.34%)
Joel Greenblatt 234,372 sh (-23.96%)
Scott Black 21,059 sh (-25.50%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, OTCPK:SSMXY, NYSE:LH, NYSE:A, NYSE:Q, NAS:DXCM, NAS:QGEN, NYSE:PKI, OTCPK:BMXMF, NYSE:BIO.B, OTCPK:SUVPF, NAS:ICLR, NYSE:CRL, NAS:CPHD, NAS:PRAH, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL » details
Traded in other countries:QDI.Germany,
Quest Diagnostics Inc is the provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates about 90% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing at its national network of 2,000 patient service centers. The firm also runs a diagnostic solutions segment which provides clinical trials testing, risk assessment services, and information technology solutions.

Ratios

vs
industry
vs
history
PE Ratio 21.97
DGX's PE Ratio is ranked higher than
65% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. DGX: 21.97 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 17.2 Max: 31.26
Current: 21.97
9.09
31.26
Forward PE Ratio 18.18
DGX's Forward PE Ratio is ranked higher than
63% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 18.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.97
DGX's PE Ratio without NRI is ranked higher than
66% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. DGX: 21.97 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.52 Max: 22.3
Current: 21.97
9.48
22.3
Price-to-Owner-Earnings 26.99
DGX's Price-to-Owner-Earnings is ranked higher than
52% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. DGX: 26.99 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.27  Med: 26.9 Max: 129.96
Current: 26.99
12.27
129.96
PB Ratio 2.95
DGX's PB Ratio is ranked higher than
58% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. DGX: 2.95 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.45 Max: 4.31
Current: 2.95
1.85
4.31
PS Ratio 1.87
DGX's PS Ratio is ranked higher than
73% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. DGX: 1.87 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.18
Current: 1.87
1.03
2.18
Price-to-Free-Cash-Flow 18.11
DGX's Price-to-Free-Cash-Flow is ranked higher than
59% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. DGX: 18.11 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.25  Med: 13.83 Max: 21.76
Current: 18.11
8.25
21.76
Price-to-Operating-Cash-Flow 13.16
DGX's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. DGX: 13.16 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.99  Med: 10.89 Max: 14.48
Current: 13.16
6.99
14.48
EV-to-EBIT 12.82
DGX's EV-to-EBIT is ranked higher than
79% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. DGX: 12.82 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 10.4 Max: 15.2
Current: 12.82
7.4
15.2
EV-to-EBITDA 10.80
DGX's EV-to-EBITDA is ranked higher than
71% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. DGX: 10.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 8.6 Max: 11.8
Current: 10.8
6.2
11.8
PEG Ratio 4.21
DGX's PEG Ratio is ranked lower than
67% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. DGX: 4.21 )
Ranked among companies with meaningful PEG Ratio only.
DGX' s PEG Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.76 Max: 5.11
Current: 4.21
0.81
5.11
Shiller PE Ratio 24.43
DGX's Shiller PE Ratio is ranked higher than
83% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. DGX: 24.43 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.47  Med: 19.87 Max: 37.46
Current: 24.43
14.47
37.46
Current Ratio 1.56
DGX's Current Ratio is ranked lower than
71% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. DGX: 1.56 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.26 Max: 1.94
Current: 1.56
0.89
1.94
Quick Ratio 1.48
DGX's Quick Ratio is ranked lower than
67% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. DGX: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.19 Max: 1.83
Current: 1.48
0.82
1.83
Days Inventory 6.48
DGX's Days Inventory is ranked higher than
93% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.07 vs. DGX: 6.48 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.48  Med: 7.69 Max: 8.46
Current: 6.48
6.48
8.46
Days Sales Outstanding 44.98
DGX's Days Sales Outstanding is ranked higher than
72% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. DGX: 44.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 44.98
40.51
48.01
Days Payable 20.64
DGX's Days Payable is ranked lower than
86% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. DGX: 20.64 )
Ranked among companies with meaningful Days Payable only.
DGX' s Days Payable Range Over the Past 10 Years
Min: 16.4  Med: 18.43 Max: 21.87
Current: 20.64
16.4
21.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.68
DGX's Dividend Yield % is ranked higher than
73% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.82 vs. DGX: 1.68 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.6  Med: 0.86 Max: 2.46
Current: 1.68
0.6
2.46
Dividend Payout Ratio 0.45
DGX's Dividend Payout Ratio is ranked lower than
70% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. DGX: 0.45 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: 0.45
Current: 0.45
0.1
0.45
3-Year Dividend Growth Rate 10.60
DGX's 3-Year Dividend Growth Rate is ranked lower than
59% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.20 vs. DGX: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 55.4
Current: 10.6
0
55.4
Forward Dividend Yield % 1.82
DGX's Forward Dividend Yield % is ranked higher than
71% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.16 vs. DGX: 1.82 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 7.10
DGX's 5-Year Yield-on-Cost % is ranked higher than
95% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. DGX: 7.10 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.53  Med: 3.63 Max: 10.39
Current: 7.1
2.53
10.39
3-Year Average Share Buyback Ratio 1.60
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.6 Max: 7
Current: 1.6
-16.9
7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.29
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
73% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. DGX: 1.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.71  Med: 0.89 Max: 2.6
Current: 1.29
0.71
2.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.05
DGX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
76% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.85 vs. DGX: 2.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.39
DGX's Price-to-Median-PS-Value is ranked lower than
73% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. DGX: 1.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.03 Max: 1.48
Current: 1.39
0.24
1.48
Price-to-Peter-Lynch-Fair-Value 4.26
DGX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
84% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.75 vs. DGX: 4.26 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DGX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.41 Max: 4.26
Current: 4.26
0.7
4.26
Earnings Yield (Greenblatt) % 7.79
DGX's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. DGX: 7.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.6  Med: 9.6 Max: 13.6
Current: 7.79
6.6
13.6
Forward Rate of Return (Yacktman) % 9.90
DGX's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. DGX: 9.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.9  Med: 14.5 Max: 25.2
Current: 9.9
9.9
25.2

More Statistics

Revenue (TTM) (Mil) $7,515
EPS (TTM) $ 4.50
Beta0.91
Short Percentage of Float4.36%
52-Week Range $69.62 - 100.00
Shares Outstanding (Mil)137.50

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 7,667 7,807 7,977
EPS ($) 5.42 5.68 6.14
EPS without NRI ($) 5.42 5.68 6.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.78%
Dividends per Share ($) 1.72 1.85 2.10
» More Articles for NYSE:DGX

Headlines

Articles On GuruFocus.com
3 Dividend Stocks for 2017 Feb 13 2017 
6 Stocks With High Business Predictability Jan 31 2017 
7 Profitable Companies With Strong Yields Jan 10 2017 
A Solid 13% Dividend Increase, Compelling Valuation Nov 28 2016 
6 Stocks to Watch Oct 04 2016 
7 Best Stocks For Value Investors This Week - 7/30/16 Aug 01 2016 
Companies Hit 52-Week Highs Jul 19 2016 
Royce Special Equity Multi-Cap Fund Mar 22 2016 
Baron Growth Fund New Purchases Part 3 Feb 08 2016 
Popular Guru Stocks With High, Growing Yield Feb 03 2016 

More From Other Websites
ETFs with exposure to Quest Diagnostics, Inc. : March 27, 2017 Mar 27 2017
Americans struggling with opioid addiction miss 50% more work than everyone else Mar 22 2017
Quest Diagnostics, Inc. :DGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Analysts Chime in on Corning, Quest Diagnostics, Canadian Pacific, Norfolk Southern, and More Mar 14 2017
Quest Diagnostics To Speak At The Barclays Global Healthcare Conference Mar 07 2017
Quest Diagnostics and American Diabetes Association® to Help Identify People at Risk for Type 2... Mar 06 2017
QUEST DIAGNOSTICS INC Financials Feb 28 2017
QUEST DIAGNOSTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 24 2017
Quest Diagnostics Declares Quarterly Cash Dividend Feb 21 2017
Quest Diagnostics Named One of 2017 "World's Most Admired Companies" by Fortune Magazine Feb 16 2017
Quest Diagnostics: Harvard Pilgrim Health Care Partners with Physicians to Close Costly Gaps in Care Feb 16 2017
Quest Diagnostics and PeaceHealth to Increase Access to Innovative, High-Value Laboratory Services... Feb 15 2017
3 Dividend Stocks for 2017 Feb 13 2017
Quest Diagnostics Partners with Veracyte for Cancer Testing Feb 09 2017
Veracyte to Expand Patient Access to the Afirma® Gene Expression Classifier In Thyroid Cancer... Feb 08 2017
ETFs with exposure to Quest Diagnostics, Inc. : February 2, 2017 Feb 02 2017
Quest Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : DGX-US : January... Jan 31 2017
Quest Diagnostics, Inc. :DGX-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017 Jan 30 2017
Edited Transcript of DGX earnings conference call or presentation 26-Jan-17 1:30pm GMT Jan 26 2017
Quest Diagnostics (DGX) Tops Q4 Earnings, Offers '17 View Jan 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)